Respiratory

Educational resources

20220721 Trixeo PSC - digital

Trixeo® Aerosphere® (formoterol fumarate, glycopyrronium, and budesonide)

Commissioned and funded by AstraZeneca Limited

This promotional prescribing summary card has been developed from content provided by AstraZeneca Limited. Information intended for UK healthcare professionals only.
View Trixeo (formoterol fumarate dihydrate/ glycopyrronium/ budesonide) prescribing information and adverse event reporting information
View Bevespi (glycopyrronium/formoterol fumarate dihydrate) prescribing information and adverse event reporting information
GB-37843
Date of preparation: July 2022

DuoResp Spiromax (budesonide:formoterol) prescribing summary card

DuoResp® Spiromax® (budesonide/formoterol)

Commissioned by Teva UK Limited

This promotional prescribing summary card has been developed from content provided by Teva UK Limited. Information intended for UK healthcare professionals only.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Teva UK Limited on 0207 540 7117 or medinfo@tevauk.com.

Click here for prescribing information and adverse event reporting

DUOR-GB-00117
Date of preparation: March 2022

AdobeStock_212764468

Identifying and managing allergic rhinitis in the asthma population

By Development Group—Scadding Holmes Ryan and Williams

This management algorithm was developed by a multidisciplinary expert panel: Scadding et al with the support of an educational grant from Mylan.

An inhaler in WPG Yellow

Inhaler choice guideline

By Development group—Usmani Capstick Saleem Scullion

This management algorithm was developed by a multidisciplinary expert panel: Usmani et al and supported by Chiesi Ltd through the provision of a grant for its production.